[
  {
    "ts": null,
    "headline": "Northwell Health named to TIME100 Most Influential Companies 2025 list",
    "summary": "NEW HYDE PARK, N.Y., June 26, 2025--For the first time, TIME has named Northwell Health, the largest health system in the Northeast, to its TIME100 Most Influential Companies 2025 list. Northwell is the only health system to be recognized on the prestigious list which highlights companies making a difference in 2025, acknowledging innovation, ambition and success. TIME aims to showcase diverse forms of influence and offer examples of impactful corporate leadership. Other companies on the list in",
    "url": "https://finnhub.io/api/news?id=712623e6dfc5ee57dd40339d91c2f5273ce2b0aa03fc25497a0e98eb9bd31e78",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750956300,
      "headline": "Northwell Health named to TIME100 Most Influential Companies 2025 list",
      "id": 135575987,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "NEW HYDE PARK, N.Y., June 26, 2025--For the first time, TIME has named Northwell Health, the largest health system in the Northeast, to its TIME100 Most Influential Companies 2025 list. Northwell is the only health system to be recognized on the prestigious list which highlights companies making a difference in 2025, acknowledging innovation, ambition and success. TIME aims to showcase diverse forms of influence and offer examples of impactful corporate leadership. Other companies on the list in",
      "url": "https://finnhub.io/api/news?id=712623e6dfc5ee57dd40339d91c2f5273ce2b0aa03fc25497a0e98eb9bd31e78"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
    "summary": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=b3a3ff1ae5165d4af0e97fd7002aa991a877e732a3452ef298813a2120742fca",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750955820,
      "headline": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
      "id": 135594669,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=b3a3ff1ae5165d4af0e97fd7002aa991a877e732a3452ef298813a2120742fca"
    }
  },
  {
    "ts": null,
    "headline": "Kymera weakness a buying opportunity, says Stifel",
    "summary": "Stifel analyst Alex Thompson is reiterating a Buy rating on Kymera Therapeutics (KYMR) following “a slate of updates,” including the decision by partner Sanofi (SNY) to discontinue development of lead IRAK4 degrader KT-474 in favor of next-gen KT-485 and a new partnership deal with Gilead (GILD) for a CDK2 molecular glue degrader. While the update related to IRAK4 is “disappointing and removes potential catalysts” next year, Sanofi expects to move KT-485 into Phase 1 next year and the broader pa",
    "url": "https://finnhub.io/api/news?id=467598c344e5a401d00d2d10ccb5178fcb46476ad3c7b92b2e772b2606a66027",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750949142,
      "headline": "Kymera weakness a buying opportunity, says Stifel",
      "id": 135559264,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Stifel analyst Alex Thompson is reiterating a Buy rating on Kymera Therapeutics (KYMR) following “a slate of updates,” including the decision by partner Sanofi (SNY) to discontinue development of lead IRAK4 degrader KT-474 in favor of next-gen KT-485 and a new partnership deal with Gilead (GILD) for a CDK2 molecular glue degrader. While the update related to IRAK4 is “disappointing and removes potential catalysts” next year, Sanofi expects to move KT-485 into Phase 1 next year and the broader pa",
      "url": "https://finnhub.io/api/news?id=467598c344e5a401d00d2d10ccb5178fcb46476ad3c7b92b2e772b2606a66027"
    }
  },
  {
    "ts": null,
    "headline": "Morning Movers: General Mills dips following fourth quarter report",
    "summary": "Futures are flat to slightly higher as the Israel‑Iran ceasefire remains stable and investor focus shifts to another day of testimony from Fed Chair Powell. Oil prices have steadied around $65-$66 per barrel after a recent drop, easing inflation pressures and supporting equities. Treasury yields and the dollar have softened, buoyed by speculation that the Fed may cut rates as soon as July or September. Equities closed near record highs yesterday as tech remains in favor, led by chipmakers such a",
    "url": "https://finnhub.io/api/news?id=be1502a47fa6c2bd8d27c17290d5115fa05a36ff2c0040a5624df7a3ab3e0b1f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750943172,
      "headline": "Morning Movers: General Mills dips following fourth quarter report",
      "id": 135558808,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Futures are flat to slightly higher as the Israel‑Iran ceasefire remains stable and investor focus shifts to another day of testimony from Fed Chair Powell. Oil prices have steadied around $65-$66 per barrel after a recent drop, easing inflation pressures and supporting equities. Treasury yields and the dollar have softened, buoyed by speculation that the Fed may cut rates as soon as July or September. Equities closed near record highs yesterday as tech remains in favor, led by chipmakers such a",
      "url": "https://finnhub.io/api/news?id=be1502a47fa6c2bd8d27c17290d5115fa05a36ff2c0040a5624df7a3ab3e0b1f"
    }
  },
  {
    "ts": null,
    "headline": "KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update",
    "summary": "Kymera's shares drop as Sanofi ends KT-474 development, but Gilead's oncology deal remains positive.",
    "url": "https://finnhub.io/api/news?id=eef169c52070c0f7580599545db16ba788e993dbda96e76d3814e8e3cc7f2182",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750941600,
      "headline": "KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update",
      "id": 135559266,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Kymera's shares drop as Sanofi ends KT-474 development, but Gilead's oncology deal remains positive.",
      "url": "https://finnhub.io/api/news?id=eef169c52070c0f7580599545db16ba788e993dbda96e76d3814e8e3cc7f2182"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences : Cyprus EFPIA Report 2024 (In English) (gilead sciences efpia report 2024 in english cyprus)",
    "summary": "Date of Publication:30/6/2025 Full Name ...",
    "url": "https://finnhub.io/api/news?id=c50f6244074a9e8b89fe6ae5a9cd5110d75906bed88ddf90cc3a01c3a49ab350",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750926189,
      "headline": "Gilead Sciences : Cyprus EFPIA Report 2024 (In English) (gilead sciences efpia report 2024 in english cyprus)",
      "id": 135556486,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "Date of Publication:30/6/2025 Full Name ...",
      "url": "https://finnhub.io/api/news?id=c50f6244074a9e8b89fe6ae5a9cd5110d75906bed88ddf90cc3a01c3a49ab350"
    }
  }
]